STGen Bio to Participate in BIX 2025, Showcasing Global Competitiveness

Strength Lies in Globally Certified Quality

STGen Bio announced on October 13 that it will participate in the "BioPlus Interphex Korea 2025 (BIX 2025)," considered the largest bioindustry exhibition in Korea, held at COEX in Seoul from October 15 to 17, for the third consecutive year to promote its technological capabilities.

A bird's-eye view of the BIX 2025 booth of STGen Bio. STGen Bio

BIX 2025, hosted by the Korea Biotechnology Industry Organization and supported by the Seoul Metropolitan Government and the Ministry of Trade, Industry and Energy, brings together global pharmaceutical and bio companies, research institutes, and academic professionals to share the latest technologies and industry trends. In particular, there is active collaboration and exchange in a variety of fields, including innovative new drug development, advanced therapeutics, pharmaceutical manufacturing processes, and clinical and non-clinical research services.

Since 2023, STGen Bio has set up an independent booth for three consecutive years, actively continuing its business networking efforts. The company also plans to expand business meetings with potential clients by providing a dedicated meeting space within the booth.

Last year, STGen Bio successfully passed inspections by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) at once, demonstrating its operation of high-quality biopharmaceutical manufacturing facilities. The company is also producing and supplying the biosimilar Imyuldosa to the United States and Europe, and has continued its achievements this year by securing orders from domestic and international pharmaceutical companies.

This year, in particular, STGen Bio has been showcasing its strengths on various international stages, including the Bio International Convention held in the United States in May, Interphex Tokyo in Japan in July, and now BIX 2025.

A representative from STGen Bio stated, "We plan to expand our harvest line by 2027 and significantly increase production capacity by introducing Pre-filled Syringe (PFS) facilities by 2029," adding, "We will strive to provide the best possible service to meet the diverse needs of our clients based on quality."

Meanwhile, STGen Bio, a subsidiary of Dong-A Socio Holdings, provides contract manufacturing organization (CMO) services for biopharmaceuticals. The company operates facilities capable of producing approximately 9,000 liters of drug substance (DS) and finished drug products (DP) in pre-filled syringe (PFS) formulations.

This content was produced with the assistance of AI translation services.